Author

Elizabeth L. Siegler

Mayo ClinicORCID 0000-0002-8336-4373Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Organism:mouse· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Brooke L. KimballiD· 2 shared Carli M. StewartiD· 2 shared Abba Zubair· 1 shared Adam J. DupuyiD· 1 shared Adam L. BurrackiD· 1 shared Alex T. LarssoniD· 1 shared Alexander K. TsaiiD· 1 shared Aylin Alasonyalılar DemireriD· 1 shared

Activity by Year

2020-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Brooke L. KimballORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Sleeping Beauty mutagenesis identifies BACH2 and other regulators of CD8+T cell exhaustion, persistence in vivo, and CAR-T function under tumor-associated chronic antigen stimulation

Chang-Jung Lee, Alex T. Larsson, Tyler A. Jubenville, Wendy A. Hudson, Zachary J. Seeman, Carli M. Stewart, Alexander K. Tsai, Adam L. Burrack, Brooke L. Kimball, Elizabeth L. Siegler, Vianca V. Vianzon, Erin E. Nolan, Yu-Ling Yang, Christopher M. Stehn, Daryl M. Gohl, , David A. Largaespada

The paper uses Sleeping Beauty mutagenesis to identify BACH2 and other genes that enhance CD8+ T cell persistence and function under chronic antigen stimulation, improving engineered T cell therapies.

Journal for ImmunoTherapy of Cancer · Jul 1, 2026Peer-reviewedImmunology

Optimized CART Cell Therapy for Metastatic Aggressive Thyroid Cancer

Claudia Manriquez Roman, Elizabeth L. Siegler, Justyna Trynda, Truc N Huynh, Grace E. DeFranco, Aylin Alasonyalılar Demirer, Matthew L. Pawlush, Michael Redig, Skyeler M. Klinge, Long K. Mai, James L. Miller, Erin E. Miller, Brooke L. Kimball, Erin E. Tapper, Reona Leo Sakemura, , Saad S. Kenderian

This paper develops a TSHR-targeted CART cell therapy for thyroid cancer and shows that combining it with MAPK inhibitors improves antitumor efficacy in dedifferentiated thyroid cancers.

bioRxiv · Mar 15, 2024 · PreprintImmunology

ERK activation in CAR T cells is amplified by CD28-mediated increase in CD3ζ phosphorylation

Jennifer A. Rohrs, Elizabeth L. Siegler, Pin Wang, Stacey D. Finley

The paper constructs a computational model of CAR T cell activation, showing CD28 enhances ERK activation by increasing CD3ζ phosphorylation kinetics.

iScience · Mar 30, 2020Peer-reviewedSystems Biology